EASD: Lilly, BI tout new Jardiance kidney analysis as rival J&J nears FDA nod

Eli Lilly and Boehringer Ingelheim unveiled new Jardiance data showing the drug's effects on cardiovascular death and kidney outcomes were consistent even in patients with advanced kidney disease, the companies said Tuesday.